This study assessed the direct costs of using Palivizumab for RSV prevention in the Foggia District, Italy, during the 2023/2024 season, and explored the cost savings coming from reallocating resources to Nirsevimab in a universal RSV program. Switching from Palivizumab to Nirsevimab could protect 57.85 % of newborns per season. Considering also hospitalization expenses, coverage reaches 46.4 % of infants, or 66.2 % if unspecified bronchiolitis is included. These results suggest notable cost savings and greater coverage, supporting a universal RSV initiative.
Cost of universal immunization with Nirsevimab vs. standard of practice for infants in their first RSV season. Foggia District, Italy, 2023–2024
Fortunato, Francesca;Martinelli, Domenico;Ascatigno, Leonardo;Campanozzi, Angelo;Iannelli, Giuseppina;Piano, Giuseppe;Trerotoli, Paolo;Prato, Rosa
2025-01-01
Abstract
This study assessed the direct costs of using Palivizumab for RSV prevention in the Foggia District, Italy, during the 2023/2024 season, and explored the cost savings coming from reallocating resources to Nirsevimab in a universal RSV program. Switching from Palivizumab to Nirsevimab could protect 57.85 % of newborns per season. Considering also hospitalization expenses, coverage reaches 46.4 % of infants, or 66.2 % if unspecified bronchiolitis is included. These results suggest notable cost savings and greater coverage, supporting a universal RSV initiative.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
